SRTS earnings

Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced the company will report financial results for the first quarter of 2026 on Thursday, May 7, 2026. Management will hold a conference call beginning at 4:30 pm Eastern time to review the results, provide a business update and answer questions. Participants are encouraged to pre-register for the conference call using this link to receive a unique dial-in number to bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. Those unable to pre

2026 CMS Physician Fee Schedule Final Rule provides a 300% per-fraction increase to delivery code that became effective January 1, 2026 Company enters 2026 with reimbursement certainty and strategic visibility, expects sequential-quarter revenue growth in Q1 and full-year profitability Shipped 14 SRT systems in Q4, most in December and none to its historically largest customer, up from six systems in Q3 excluding shipments to its historically largest customer Conference call begins at 4:30 p.m. Eastern time today Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for onc

Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the company will report fourth quarter and full year 2025 financial results on Thursday, February 12, 2026. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions. Participants are encouraged to pre-register for the conference call using this link to receive a dial-in number and PIN to bypass the live operator. Participants may pre-register at any time, including up to and after t

Centers for Medicare & Medicaid Services (CMS) established coding validating superficial radiotherapy (SRT) for treating non-melanoma skin cancer Revenues of $6.9 million Shipped 16 SRT systems including three to China Fair Deal Agreement (FDA) treatment volume increased 20% over the second quarter Exited the quarter with $24.5 million in cash and no debt Conference call begins at 4:30 p.m. Eastern time today Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and nine months end

Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the company will report financial results for the third quarter of 2025 on Thursday, November 6, 2025. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions. Participants are encouraged to pre-register for the conference call using this link to receive a unique dial-in number to bypass the live operator. Participants may pre-register at any time, including up to and after the cal

Shipped 19 SRT systems during the quarter, including four to China Revenues of $7.3 million FDA treatment volume increased 27% over the first quarter Exited the quarter with $22.2 million in cash and no debt Proposed Physician Fee Schedule expected to favorably impact adoption of SRT technology beginning in 2026 Conference call begins at 4:30 p.m. Eastern time today Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and six months ended June 30, 2025. Highlights of the

Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the company will report financial results for the second quarter of 2025 on Thursday, August 7, 2025. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions. Participants are encouraged to pre-register for the conference call using this link to receive a unique dial-in number to bypass the live operator. Participants may pre-register at any time, including up to and after the call

21 SRT systems shipped during the quarter; revenues of $8.3 million 65% increase in treatment volume from FDAs over preceding quarter Profitability forecast for the next three quarters and for the full year Conference call begins at 4:30 p.m. Eastern time today Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three months ended March 31, 2025. Highlights of the first quarter of 2025 include the following: Revenues were $8.3 million Net loss was $2.6 million, or $(0.16) per share Shi

Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the company will report financial results for the first quarter of 2025 on Thursday, May 15, 2025. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions. Participants are encouraged to pre-register for the conference call using this link to receive a unique dial-in number to bypass the live operator. Participants may pre-register at any time, including up to and after the call sta

Shipped a record 39 SRT systems during the quarter; revenues of $13.1 million Achieved fifth consecutive quarter of profitability; diluted EPS of $0.09 Conference call begins at 4:30 p.m. Eastern time today Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and 12 months ended December 31, 2024. Highlights include the following: Revenues were $13.1 million for the fourth quarter and $41.8 million for the year, up 4% and 71% respectively, compared with the prior year Net income

Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the company will report financial results for the 2024 fourth quarter and full year on Wednesday, February 5, 2025. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions. Participants are encouraged to pre-register for the conference call using this link to receive a unique dial-in number to bypass the live operator. Participants may pre-register at any time, including up to and

This revised news release replaces the one issued on November 14, 2024, contains several non-financial changes throughout and removes the name of and references to a new customer, at the customer's request. The agreement with the new customer remains in effect. Revenues of $8.8 million compare with $3.9 million in the prior-year quarter, adjusted EBITDA (a non-GAAP measure) of $1.6 million compares with negative $1.7 million a year ago Expects to have more than 50 IG-SRT Systems signed under the Fair Deal Agreement recurring-revenue program by the end of the year BOCA RATON, Fla, Nov. 17, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializin

Revenues of $8.8 million compare with $3.9 million in the prior-year quarter, adjusted EBITDA (a non-GAAP measure) of $1.6 million compares with negative $1.7 million a year agoSigned a Fair Deal Agreement with Platinum Dermatology, a leading dermatology network with 130 clinics across the U.S. Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and nine months ended September 30, 2

BOCA RATON, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, November 14, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the third quarter of 2024. In addition, management will provide a business update and a discussion on recent and upcoming milestones. Participants are encouraged to pre-register for the conference call using this link. Upon registration participants will receive a unique dial-in number that will permit them to bypass

Revenues of $9.2 million compares with $4.5 million in the prior-year quarter, adjusted EBITDA (a non-GAAP measure) of $2.1 million compares with negative $1.0 million a year ago"Fair Deal Agreement" recurring revenue program gaining momentum with 15 agreements signed to date Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and six months ended June 30, 2024. Highlights from the

BOCA RATON, Fla. , Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, reminds investors that management will hold a conference call on Thursday, August 8, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the second quarter of 2024. In addition, management will provide a business update and a discussion on recent and upcoming milestones. Participants are encouraged to pre-register for the conference call using this link. Upon registration participants will receive a unique dial in number that will permit them to

BOCA RATON, Fla., July 25, 2024 (GLOBE NEWSWIRE) --  Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, August 8, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the second quarter of 2024. In addition, management will provide a business update and a discussion on recent and upcoming milestones. Participants are encouraged to pre-register for the conference call using this link. Upon registration participants will receive a unique dial in number that will permit them to bypass the

Revenues of $10.7 million, compared with $3.4 million in the prior-year quarter; Adjusted EBITDA (a non-GAAP measure) of $3.0 million, compared with negative $2.7 million in the prior-year quarterLaunched the "Fair Deal Agreement" recurring revenue program to provide an equipment placement option and complement the fair market value lease program for SRT systems Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financ

Reminder: First Quarter 2024 Financial Results Reporting and Conference Call on May 9, 2024 BOCA RATON, Fla, May 06, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces the sale of the first SRT-100 Vision™ (IG-SRT) system in Asia, to Far Eastern Memorial Hospital in Taiwan.  The hospital, which has more than 1,000 beds, is one of the largest private hospitals in Taiwan. Far Eastern Memorial Hospital also plans to publish research on possible new indications for the SRT-100 Vision (IG-SRT), which may be instrumental in

BOCA RATON, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, reminds investors that management will hold a conference call on Thursday, May 9, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the first quarter of 2024. In addition, management will provide a business update and a discussion on recent and upcoming milestones.  Participants are encouraged to pre-register for the conference call using this link. Upon registration participants will receive a unique dial in number that will permit them to

BOCA RATON, Fla. , April 18, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, May 9, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the first quarter of 2024. In addition, management will provide a business update and a discussion on recent and upcoming milestones. Participants are encouraged to pre-register for the conference call using this link. Upon registration participants will receive a unique dial in number that will permit them to bypass the liv

Fourth quarter revenues of $12.6 million up three-fold sequentially, reflect ongoing customer adjustment to macroeconomic conditionsIntroduces recurring revenue model for the SRT-100 Vision™ (IG-SRT) to address dermatologist demand Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the three and 12 months ended December 31, 2023. Highlights from the fourth quarter of 2023 and recent weeks

BOCA RATON, Fla. , Jan. 30, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, February 8, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the fourth quarter and full year 2023. In addition, management will provide a business update and a discussion on recent and upcoming milestones. Participants are encouraged to pre-register for the conference call using this link. Upon registration participants will receive a unique dial in number that will permit t

Ships more than 60 SRT units in 2023To report full financial results and hold conference call on February 8th BOCA RATON, Fla. , Jan. 23, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, today announces preliminary unaudited financial results for the three and 12 months ended December 31, 2023. The company expects to report revenue for the fourth quarter of 2023 of more than $12 million, with full-year revenue expected to exceed $23 million.   "We are delighted to report a strong upti

   Revenues of $3.9 million reflect seasonality and macroeconomic conditions Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the three and nine months ended September 30, 2023. Highlights from the third quarter of 2023 and recent weeks include the following: Reported revenues of $3.9 million, compared with $4.5 million in the second quarter of 2023 and $9.0 million in the prior-year third qu

BOCA RATON, Fla, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, November 9, 2023 at 4:30 p.m. Eastern time to discuss the financial results for the third quarter of 2023. In addition, management will provide a business update and a discussion on recent and upcoming milestones. Participants are encouraged to pre-register for the conference call using this link. Upon registration participants will receive a unique dial in number that will permit them to bypass t

Revenues increased 33% and system shipments increased 30%, both compared with the first quarter of 2023Achieved a milestone with the installation of 700 systems for a total of 708 Expects to ship at least 60 SRT units during 2023 and to return to profitability in the second half of the year Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the three and six months ended June

BOCA RATON, Fla., July 26, 2023 (GLOBE NEWSWIRE) --  Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, August 3, 2023 at 4:30 p.m. Eastern time to discuss the financial results for the second quarter of 2023. In addition, management will provide a business update and a discussion on recent and upcoming milestones. Participants are encouraged to pre-register for the conference call using this link. Upon registration participants will receive a unique dial in number that will permit them to bypass

Lower demand for SRT systems reflects the impact of inflation on dermatologists' cash flow from fewer elective aesthetic procedures and higher operating costs Sensus expects to ship more than 60 SRT units during 2023 and return to profitability in the second half of the year Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., May 03, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the three months ended March 31, 2023. Highlights from the firs

BOCA RATON, Fla. , April 25, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Wednesday, May 3, 2023 at 4:30 p.m. Eastern time to discuss the financial results for the first quarter of 2023. In addition, management will provide a business update and a discussion on recent and upcoming milestones. Participants are encouraged to pre-register for the conference call using this link. Upon registration participants will receive a unique dial in number that will permit them to bypass the li

Full-year revenues increased 65% to $44.5 million Investments in technology and staff position Sensus for growth in 2023 and beyond Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions (Company or Sensus), announces financial results for the three and 12 months ended December 31, 2022. Highlights from the fourth quarter of 2022 and recent weeks include the following (all comparisons are with the fourth quarter of 2021, unless o

BOCA RATON, Fla., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, February 9, 2023 at 4:30 p.m. Eastern time to discuss the financial results for the fourth quarter and full year 2022. In addition, management will provide a business update and a discussion on recent and upcoming milestones. To access the conference call, the dial-in numbers are 844-481-2811 (U.S. and Canada Toll Free), 412-317-0676 (International). Please direct the operator to be connected to th

Fourth quarter revenues to exceed $13 million; full year revenues to exceed $44 million, representing growth of 60% BOCA RATON, Fla, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, today reports preliminary 2022 fourth quarter and full year revenues. Preliminary revenues for the three months ended December 31, 2022 are expected to exceed $13 million.  For the full year 2022, revenues are expected to exceed $44 million, representing growth of approximately 60% over 2021.  Fourth quarter 2022

Profitability continues with revenues up 64% to $9.0 million, diluted EPS of $0.11 compares with $0.01 a year ago Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the three and nine months ended September 30, 2022. Highlights from the third quarter of 2022 and recent weeks include the following (all comparisons are with the third quarter of 2021, unless otherwise indicated): Revenues were $9.

BOCA RATON, Fla., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, November 3, 2022 at 4:30 p.m. Eastern time to discuss the financial results for the third  quarter of 2022. In addition, management will provide a business update and a discussion on recent and upcoming milestones. To access the conference call, the dial-in numbers are 866-777-2509 (U.S. and Canada Toll Free), 412-317-5413 (International). Please direct the operator to be connected to the Sensus He

Diluted EPS of $0.21 compares with $(0.02) for the year-ago quarter Affirms expectations for full-year profitability Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the three and six months ended June 30, 2022. Highlights from the second quarter of 2022 and recent weeks include the following (all comparisons are with the second quarter of 2021, unless otherwise indicated): Revenues were $12.

BOCA RATON, Fla., July 26, 2022 (GLOBE NEWSWIRE) --  Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, August 4, 2022 at 4:30 p.m. Eastern time to discuss the financial results for the second quarter of 2022. In addition, management will provide a business update and a discussion on recent and upcoming milestones. To access the conference call, the dial-in numbers are 888-390-3967 (U.S. and Canada Toll Free), 862-298-0702 (International). Please direct the operator to be connected to the Sensus H

BOCA RATON, Fla, April 21, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, May 5, 2022 at 4:30 p.m. Eastern time to discuss the financial results for the first quarter of 2022. In addition, management will provide a business update and a discussion on recent and upcoming milestones. To access the conference call, the dial-in numbers are 888-390-3967 (U.S. and Canada Toll Free), 862-298-0702 (International). Please direct the operator to be connected to the Sensus Health

4Q21 diluted EPS of $0.32 on revenues of $13.0 million up 433% and 156%, respectively Affirms expectations for 1Q22 continued growth and full-year 2022 profitability Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive, and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the three and 12 months ended December 31, 2021. Highlights from the fourth quarter of 2021 and recent weeks include th

BOCA RATON, Fla, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, February 10, 2022 at 4:30 p.m. Eastern time to discuss the financial results for the fourth quarter and full year 2021. In addition, management will provide a business update and a discussion on recent and upcoming milestones. To access the conference call, the dial-in numbers are 888-390-3967 (U.S. and Canada Toll Free), 862-298-0702 (International). Please direct the operator to be connected to the

BOCA RATON, Fla., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that it expects record sales for the fourth quarter of 2021, resulting in over $25 million in sales for the year, and positive EBITDA and net income for both the fourth quarter and full year.  Fourth quarter sales include the shipment of three SRT Systems to China. Based upon expectations for shipments during the current quarter, the company also expects to be profitable for the first quarter of 2022.  Sensus expects to rep

Achieves profitability on revenues of $5.5 million, up sharply from $1.6 million a year ago Affirms expectations for continued growth in 4Q and full-year profitability Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the three and nine months ended September 30, 2021. Highlights from the third quarter of 2021 and recent weeks include the following (all comparisons are with the third quarter o

BOCA RATON, Fla, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, November 4, 2021 at 4:30 p.m. Eastern time to discuss the financial results for the third quarter of 2021. In addition, management will provide a business update and a discussion on recent and upcoming milestones. To access the conference call, the dial-in numbers are 800-285-6670 (U.S. and Canada Toll Free), 832-553-9961 (International). Please direct the operator to be connected to the Sensus H

Revenues of $5.4 million up 358% year-over-year, up 77% sequentially Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the three and six months ended June 30, 2021. Highlights from the second quarter of 2021 and recent weeks include the following (all comparisons are with the second quarter of 2020, unless otherwise indicated): Shipped 17 systems during the quarter, including four to China and

Revenues up 83% year-over-year Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., May 06, 2021 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the three months ended March 31, 2021. Highlights from the first quarter of 2021 and recent weeks include the following (all comparisons are with the first quarter of 2020, unless otherwise indicated): Installed the 500th unit since Sensus was founded 10 years ago with the sale of a second unit to Mid-Atlan

Achieves fourth quarter net income of $1.0 million on revenues of $5.1 million Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the three and 12 months ended December 31, 2020. Highlights from the fourth quarter of 2020 and recent weeks include the following (all comparisons are with the fourth quarter of 2019, unless otherwise indicated): Shipped 18 systems during th